{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000024","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.569774+00:00","generated_at":"2026-06-06T01:11:59.387626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold","bullets":["FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.","Cash and investments $295.3M as of Nov 30, 2023, up from $268.7M at Aug 31, 2023.","NX-5948 granted FDA Fast Track for CLL; positive Phase 1 data with durable responses.","NX-2127 placed on partial clinical hold by FDA; expects to resolve in 2024.","Generated $100M non-dilutive capital from partners in 2023; licensed IRAK-4 degrader NX-0479/GS-6791 to Gilead."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000024","json":"https://secwatch.observer/filing/0001549595-24-000024.json","markdown":"https://secwatch.observer/filing/0001549595-24-000024.md","text":"https://secwatch.observer/filing/0001549595-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/0001549595-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/nrix-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:11:59.387626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f980986a1da456d76ae640234d8d707ae27aeea","claim":"Nurix Therapeutics, Inc. reported financial results for the fiscal quarter and fiscal year ended November 30, 2023.","evidence_excerpt":"today reported financial results for the fiscal quarter and fiscal year ended November 30, 2023, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/0001549595-24-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and fiscal year ended November 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}